Maverick0408,
Maybe, just maybe a bigger company heard about what a smaller company was working on and wanted in on the action or was directed to it. Gee, has that ever happened before?; ). Hint, think Cognate expansion plans after NWBO had access to data which CRL was advised about from a former associate employee of NWBO. Hmmm. Maybe going BIG really means going REALLY BIG!; ). Since NWBO developed it all in house the ownership belongs to NWBO shareholders without being diluted by some big pharma interest that was not going to be incentivized to develop a partner/competitor that might cause a reduction in the use of some of their products with any sense of urgency. Think about rGBM patients and 50% survival vs 65% with checkpoint inhibitor. Not all patients benefit from temodar and checkpoint inhibitors. Personalized treatment is coming and SOC will be changed to reflect this. Best wishes.